ClinicalTrials.gg
CompletedNCT04657224Updated Aug 21, 2025

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

A Phase 1 interventional study of JNJ-64264681 and JNJ-67856633 in Lymphoma, Non-Hodgkin and Chronic Lymphocytic Leukemia, sponsored by Janssen Research & Development, LLC. Completed at 28 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson — 2 open to participants now, 7 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Johnson & Johnson.

Enrollment
9th of 15
75 · median 85
Started
2021
with 1 other
Phase 1
13 of 17
2 open now
Registered
9th of 17
by date

Among the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 1, and was the 9th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalation); and the safety of the RP2Ds for this combination in different histologies/participant populations (Part B - Cohort Expansion).

Read the detailed description

Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that plays a critical role in B cell activation via the B cell receptor (BCR) signaling pathway. BTK is important for normal B-cell activation and the pathophysiology of B cell malignancies. A few BTK inhibitors have demonstrated clinical activity in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Non-Hodgkin lymphoma represents a diverse set of diseases, of which more than 60 subtypes have been identified and classified by the world health organization. JNJ-64264681 is a second-generation, orally active, selective, and irreversible covalent inhibitor of BTK and JNJ-67856633 is an orally bioavailable, potent, and selective first in class mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor that binds to an allosteric site on MALT1 with a mixed-type mechanism. JNJ-64264681 and JNJ-67856633 inhibit BTK and MALT1, respectively, and both BTK and MALT1 are involved in transmitting the pro-survival BCR signal. The study will consist of Screening Phase (28 days); Treatment Phase (from Cycle 1 Day 1 up to end of treatment, each cycle is a 21-day cycle) and a Follow-up Phase (from end of treatment visit until lost to follow-up, withdrawal of consent, death, 6 months after start of first subsequent antineoplastic therapy, after the clinical cut off (CCO) date participants will be withdrawn from the study 30 days after the last dose of study drugs were administered). The total study duration is estimated at 2 years and 2 months. Safety assessments will include physical examinations, vital signs, electrocardiograms, clinical safety laboratory assessments, eastern cooperative oncology group performance status, echocardiogram, and adverse events monitoring.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status grade of 0 or 1
  • Cardiac parameters within the following range: interval (QTcF) \<= 480 milliseconds
  • Participants with B cell non-Hodgkin lymphoma (NHL) must have tumor tissue available at baseline as described in the protocol. This is not required for participants with chronic lymphocytic leukemia (CLL)
  • Women of must agree to use a barrier method of ; use a highly effective preferably user-independent method of contraception; not to donate eggs (ova, oocytes) or freeze them for future use for the purposes of assisted reproduction during the study; not to plan to become pregnant; and not to breast-feed

Exclusion criteria

Exclusion Criteria:

  • Part A and select cohorts in Part B: Prior treatment with JNJ 64264681 or JNJ-67856633. Previously discontinued treatment with a Bruton's tyrosine kinase (BTK) or mucosa-associated lymphoid tissue lymphoma translocation protein (MALT) inhibitor other than JNJ 64264681 or JNJ-67856633 due to participant or doctor choice without evidence of progression or intolerable class-related toxicity will be eligible
  • Known (active) central nervous system (CNS) involvement
  • Received prior solid organ transplantation
  • Participant has known allergies, , or intolerance to JNJ-64264681 or JNJ 67856633 or
  • Toxicities from previous anti-cancer therapies that have not resolved to baseline levels, or to Grade less than (\<) 2 (except for alopecia [>=Grade 2], vitiligo [Grade 2] and peripheral neuropathy [Grade 1])
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Part A: Dose escalation: JNJ-64264681 and JNJ-67856633

    Participants will receive JNJ-64264681 and JNJ-67856633 will be administered together until disease progression, intolerable toxicity, withdrawal of consent, or the investigator.

    Drug: JNJ-64264681 · Drug: JNJ-67856633

  • Experimental
    Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633

    Participants will receive JNJ-64264681 and JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.

    Drug: JNJ-64264681 · Drug: JNJ-67856633

Interventions

  • JNJ-64264681 capsules will be administered orally.

  • JNJ-67856633 capsules or tablets will be administered orally.

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with Dose-limiting Toxicity (DLT)

    Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

    Time frame: Up to 28 days

  2. Part A and Part B: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 3 years and 9 months

Secondary outcomes

  1. Plasma Concentrations of JNJ-64264681 and JNJ-67856633

    Plasma concentrations of JNJ-64264681 and JNJ-67856633 will be assessed.

    Time frame: Up to 3 years and 9 months

  2. Bruton's Tyrosine Kinase (BTK) Occupancy in Peripheral Blood Mononuclear Cell (PBMCs)

    BTK occupancy will be assessed.

    Time frame: Up to 3 years and 9 months

  3. Overall Response Rate (ORR)

    ORR is defined according to Non-Hodgkin Lymphoma, International Workshop on Chronic Lymphocytic Leukemia (iwCLL); and Response assessment in Waldenström Macroglobulinemia (IWWM).

    Time frame: Up to 3 years and 9 months

  4. Time to First Response

    Time to first response defined for the responders as the time from the date of first dose of study treatment to the date of initial documentation of a first response as defined in the disease-specific response criteria.

    Time frame: Up to 3 years and 9 months

  5. Duration of Response

    DOR will be calculated from the date of initial documentation of a response to the date of first documented evidence of relapse, as defined in the disease-specific response criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 3 years and 9 months

07

Study locations

28 sites
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Monash Medical Centre
    Clayton, 3168, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, 3000, Australia
  • Linear Clinical Research Ltd
    Nedlands, 6009, Australia
  • Scientia Clinical Research
    Randwick, 2031, Australia
  • AZ St.-Jan Brugge-Oostende AV
    Bruges, 8000, Belgium
  • Universitair Ziekenhuis Gent - UZ GENT
    Ghent, 9000, Belgium
  • CHU UCL Namur - Site Godinne
    Yvoir, 5530, Belgium
  • CHRU de Lille Hopital Claude Huriez
    Lille, 59037, France
  • Chu Hotel Dieu
    Nantes, 44093, France
  • Centre hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
  • CHU Bretonneau
    Tours, 37044, France
  • Arensia Exploratory Medicine
    Tbilisi, 0112, Georgia
  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Tel Aviv Sourasky MC
    Tel Aviv, 6423906, Israel
  • Arensia Exploratory Medicine
    Chisinau, Md2025, Moldova
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80 214, Poland
  • Pratia Onkologia Katowice
    Katowice, 40 519, Poland
  • Pratia MCM Krakow
    Krakow, 30-727, Poland
  • Centrum Medyczne Pratia Poznan
    Skorzewo, 60 185, Poland
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Seoul National University Hospital
    Seoul, 3080, South Korea
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp Univ Fund Jimenez Diaz
    Madrid, 28040, Spain
  • Medical Center of Limited Liability Company Arensia Exploratory Medicine
    Kyiv, 01135, Ukraine
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2025, 46 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 46 months is close to that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
Feb 25, 2021
Primary completionActual
Jan 16, 2025
CompletionActual
Jan 16, 2025
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04657224
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
Feb 25, 2021
Primary completion
Jan 16, 2025
Completion
Jan 16, 2025
Last update
Aug 21, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trials
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: JNJ-64264681 · Safimaltib

Start the discussion